DAVENPORT & Co LLC Has $515,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

DAVENPORT & Co LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 16.8% in the first quarter, Holdings Channel reports. The institutional investor owned 2,226 shares of the medical research company’s stock after purchasing an additional 320 shares during the period. DAVENPORT & Co LLC’s holdings in IQVIA were worth $515,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in IQV. National Bank of Canada FI acquired a new position in shares of IQVIA during the fourth quarter valued at about $928,000. Dynamic Advisor Solutions LLC raised its position in IQVIA by 7.0% in the fourth quarter. Dynamic Advisor Solutions LLC now owns 1,495 shares of the medical research company’s stock worth $422,000 after purchasing an additional 98 shares in the last quarter. Lincoln National Corp raised its position in IQVIA by 2.4% in the fourth quarter. Lincoln National Corp now owns 3,471 shares of the medical research company’s stock worth $979,000 after purchasing an additional 83 shares in the last quarter. Brown Advisory Inc. raised its position in IQVIA by 8.4% in the fourth quarter. Brown Advisory Inc. now owns 1,019 shares of the medical research company’s stock worth $288,000 after purchasing an additional 79 shares in the last quarter. Finally, Regentatlantic Capital LLC raised its position in IQVIA by 25.2% in the fourth quarter. Regentatlantic Capital LLC now owns 2,283 shares of the medical research company’s stock worth $644,000 after purchasing an additional 459 shares in the last quarter. Institutional investors and hedge funds own 87.12% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent research reports. Morgan Stanley increased their price target on shares of IQVIA from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Robert W. Baird increased their price target on shares of IQVIA from $260.00 to $265.00 in a research report on Friday. Wells Fargo & Company lowered shares of IQVIA from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $290.00 to $235.00 in a report on Monday, April 25th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of IQVIA from $250.00 to $290.00 and gave the stock a “buy” rating in a report on Tuesday, April 12th. Two investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $275.63.

IQVIA Price Performance

Shares of IQV stock opened at $221.62 on Tuesday. IQVIA Holdings Inc. has a 52-week low of $194.67 and a 52-week high of $285.61. The stock has a market cap of $41.95 billion, a PE ratio of 37.00, a PEG ratio of 1.69 and a beta of 1.33. The company has a debt-to-equity ratio of 2.36, a quick ratio of 0.93 and a current ratio of 0.96. The firm’s 50 day moving average price is $211.93 and its two-hundred day moving average price is $224.50.

IQVIA (NYSE:IQVGet Rating) last announced its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.22. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.49 billion. During the same period last year, the firm earned $1.94 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 9.46 EPS for the current year.

IQVIA Company Profile

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVGet Rating).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.